You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)注射用多西他賽(白蛋白結合型)獲臨牀試驗批件
格隆匯 05-19 18:35

格隆匯5月19日丨石藥集團(01093.HK)宣佈,公司附屬公司石藥集團中奇製藥技術(石家莊)有限公司開發的"注射用多西他賽(白蛋白結合型)"已獲中國國家藥品監督管理局批准可以在中國開展臨牀試驗。

該產品採用創新技術將多西他賽包裹於人血白蛋白中,計劃開發的適應症為實體瘤。與多西他賽注射液相比具有以下優勢:(1)安全性:無需激素預處理,可高濃度快速給藥,提高安全性及患者順應性;(2)有效性:臨牀前多個腫瘤模型中效果顯着,臨牀上可更大劑量給藥,進一步提高療效。預期該產品極有希望在臨牀研究中展現出良好的抗腫瘤治療效果。

該產品屬於化藥2類,目前全球尚無同類產品上市。集團將全力推進該產品的臨牀研究工作,力爭該產品儘快上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account